These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 34535394)

  • 1. Targeting pancreatic ductal adenocarcinoma: New therapeutic options for the ongoing battle.
    Malhotra P; Palanisamy R; Falasca M
    Hepatobiliary Pancreat Dis Int; 2022 Feb; 21(1):4-6. PubMed ID: 34535394
    [No Abstract]   [Full Text] [Related]  

  • 2. Novel drug targets based on association between inflammation and pancreatic ductal adenocarcinoma.
    Saif MW
    JOP; 2010 Jul; 11(4):403-4; author reply 411. PubMed ID: 20601821
    [No Abstract]   [Full Text] [Related]  

  • 3. Evolution of Systemic Therapy in Metastatic Pancreatic Ductal Adenocarcinoma.
    Kamgar M; Chakrabarti S; Shreenivas A; George B
    Surg Oncol Clin N Am; 2021 Oct; 30(4):673-691. PubMed ID: 34511189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Pancreatic Ductal Adenocarcinoma (PDAC).
    Parrasia S; Zoratti M; Szabò I; Biasutto L
    Cell Physiol Biochem; 2021 Jan; 55(1):61-90. PubMed ID: 33508184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current Therapeutic Options for Pancreatic Ductal Adenocarcinoma.
    Bisht S; Brossart P; Feldmann G
    Oncol Res Treat; 2018; 41(10):590-594. PubMed ID: 30286472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets.
    Sclafani F; Iyer R; Cunningham D; Starling N
    Crit Rev Oncol Hematol; 2015 Sep; 95(3):318-36. PubMed ID: 25921418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pancreatic ductal adenocarcinoma: metastatic disease.
    Muñoz Martín AJ; Adeva J; Martínez-Galán J; Reina JJ; Hidalgo M
    Clin Transl Oncol; 2017 Dec; 19(12):1423-1429. PubMed ID: 28623515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Status and future directions in the management of pancreatic cancer: potential impact of nanotechnology.
    Sielaff CM; Mousa SA
    J Cancer Res Clin Oncol; 2018 Jul; 144(7):1205-1217. PubMed ID: 29721665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonviral siRNA delivery systems for pancreatic cancer therapy.
    Aghamiri S; Raee P; Talaei S; Mohammadi-Yeganeh S; Bayat S; Rezaee D; Ghavidel AA; Teymouri A; Roshanzamiri S; Farhadi S; Ghanbarian H
    Biotechnol Bioeng; 2021 Oct; 118(10):3669-3690. PubMed ID: 34170520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma.
    Indolfi L; Ligorio M; Ting DT; Xega K; Tzafriri AR; Bersani F; Aceto N; Thapar V; Fuchs BC; Deshpande V; Baker AB; Ferrone CR; Haber DA; Langer R; Clark JW; Edelman ER
    Biomaterials; 2016 Jul; 93():71-82. PubMed ID: 27082874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer-Specific Targeting of Taurine-Upregulated Gene 1 Enhances the Effects of Chemotherapy in Pancreatic Cancer.
    Tasaki Y; Suzuki M; Katsushima K; Shinjo K; Iijima K; Murofushi Y; Naiki-Ito A; Hayashi K; Qiu C; Takahashi A; Tanaka Y; Kawaguchi T; Sugawara M; Kataoka T; Naito M; Miyata K; Kataoka K; Noda T; Gao W; Kataoka H; Takahashi S; Kimura K; Kondo Y
    Cancer Res; 2021 Apr; 81(7):1654-1666. PubMed ID: 33648930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Optimal duration and timing of adjuvant chemotherapy after resection for pancreatic ductal adenocarcinoma].
    Strobel O; Büchler MW
    Chirurg; 2014 Jun; 85(6):543. PubMed ID: 24824005
    [No Abstract]   [Full Text] [Related]  

  • 13. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
    Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
    Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts.
    Liu H; Shi Y; Qian F
    Adv Drug Deliv Rev; 2021 May; 172():37-51. PubMed ID: 33705881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. microRNA-10b: a new marker or the marker of pancreatic ductal adenocarcinoma?
    Setoyama T; Zhang X; Natsugoe S; Calin GA
    Clin Cancer Res; 2011 Sep; 17(17):5527-9. PubMed ID: 21816909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammation and pancreatic ductal adenocarcinoma: a potential scenario for novel drug targets.
    Uomo I; Miraglia S; Pastorello M
    JOP; 2010 May; 11(3):199-202. PubMed ID: 20442512
    [No Abstract]   [Full Text] [Related]  

  • 17. Transcytosis - An effective targeting strategy that is complementary to "EPR effect" for pancreatic cancer nano drug delivery.
    Liu X; Jiang J; Meng H
    Theranostics; 2019; 9(26):8018-8025. PubMed ID: 31754378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future.
    Christenson ES; Jaffee E; Azad NS
    Lancet Oncol; 2020 Mar; 21(3):e135-e145. PubMed ID: 32135117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulsed High-Intensity Focused Ultrasound Enhances Delivery of Doxorubicin in a Preclinical Model of Pancreatic Cancer.
    Li T; Wang YN; Khokhlova TD; D'Andrea S; Starr F; Chen H; McCune JS; Risler LJ; Mashadi-Hossein A; Hingorani SR; Chang A; Hwang JH
    Cancer Res; 2015 Sep; 75(18):3738-46. PubMed ID: 26216548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor Priming by SMO Inhibition Enhances Antibody Delivery and Efficacy in a Pancreatic Ductal Adenocarcinoma Model.
    Wang J; Chan DKW; Sen A; Ma WW; Straubinger RM
    Mol Cancer Ther; 2019 Nov; 18(11):2074-2084. PubMed ID: 31363010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.